Emerging Microbes and Infections (Dec 2022)
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
- Haomeng Wang,
- Zhao Chen,
- Zhenghua Wang,
- Jin Li,
- Zhihong Yan,
- Jinbo Yuan,
- Airu Zhu,
- Lan Chen,
- Ye Liu,
- Chenlong Hu,
- Ali Zhu,
- Guowei Li,
- Yuehu Li,
- Jie Deng,
- Liqiao Ma,
- Xiuwen Sui,
- Wei Miao,
- Junqiang Li,
- Xiuyu Zheng,
- Jinhua Piao,
- Yanfeng Yao,
- Juhong Rao,
- Chao Shan,
- Zhiming Yuan,
- Jincun Zhao,
- Tao Zhu
Affiliations
- Haomeng Wang
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Zhao Chen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
- Zhenghua Wang
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Jin Li
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Zhihong Yan
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Jinbo Yuan
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Airu Zhu
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
- Lan Chen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
- Ye Liu
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Chenlong Hu
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Ali Zhu
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Guowei Li
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Yuehu Li
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- Jie Deng
- CanSino Biologics, Tianjin, People’s Republic of China
- Liqiao Ma
- CanSino Biologics, Tianjin, People’s Republic of China
- Xiuwen Sui
- CanSino Biologics, Tianjin, People’s Republic of China
- Wei Miao
- CanSino Biologics, Tianjin, People’s Republic of China
- Junqiang Li
- CanSino Biologics, Tianjin, People’s Republic of China
- Xiuyu Zheng
- CanSino Biologics, Tianjin, People’s Republic of China
- Jinhua Piao
- CanSino Biologics, Tianjin, People’s Republic of China
- Yanfeng Yao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Juhong Rao
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Chao Shan
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Zhiming Yuan
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China
- Jincun Zhao
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China
- Tao Zhu
- CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China
- DOI
- https://doi.org/10.1080/22221751.2022.2081616
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1550 – 1553
Abstract
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
Keywords
